Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Lars Gedda

Showing results (41-50 of 63) with videos related to

Pageof 7
Sort By:
European Journal of Pharmaceutical Sciences : Official Journal of the European Federation for Pharmaceutical Sciences|December 27, 2024
Novel thermosensitive small multilamellar lipid nanoparticles with promising release characteristics made by dual centrifugationJonas K Koehler, Stefanie Schmager, Johannes Schnur, et al.
Journal of Materials Science. Materials in Medicine|January 31, 2014
Pre-incubation of chemically crosslinked hyaluronan-based hydrogels, loaded with BMP-2 and hydroxyapatite, and its effect on ectopic bone formationSonya Stenfelt, Gry Hulsart-Billström, Lars Gedda, et al.
Cancer Biotherapy & Radiopharmaceuticals|June 10, 2004
[177Lu]Bz-DTPA-EGF: Preclinical characterization of a potential radionuclide targeting agent against gliomaAsa Liljegren Sundberg, Lars Gedda, Anna Orlova, et al.
Cancer Biotherapy & Radiopharmaceuticals|October 25, 2002
Comparative biodistribution of the radiohalogenated (Br, I and At) antibody A33. Implications for in vivo dosimetryAnna Orlova, Johanna Höglund, Mark Lubberink, et al.
Tumour Biology : the Journal of the International Society for Oncodevelopmental Biology and Medicine|June 18, 2002
A new antibody recognizing the vIII mutation of human epidermal growth factor receptorLinda Ohman, Lars Gedda, Göran Hesselager, et al.
Physical Chemistry Chemical Physics : PCCP|January 6, 2023
Excited-state and charge-carrier dynamics in binary conjugated polymer dots towards efficient photocatalytic hydrogen evolutionAijie Liu, Sicong Wang, Hongwei Song, et al.
Plos One|July 7, 2012
Cellular effects of HER3-specific affibody moleculesLovisa Göstring, Magdalena Malm, Ingmarie Höidén-Guthenberg, et al.
International Journal of Pharmaceutics|April 26, 2021
Formulation development and upscaling of lipid nanocapsules as a drug delivery system for a novel cyclic GMP analogue intended for retinal drug deliveryDileep Urimi, Ronja Widenbring, Raúl Oswaldo Pérez García, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|April 29, 2006
111In-benzyl-DTPA-ZHER2:342, an affibody-based conjugate for in vivo imaging of HER2 expression in malignant tumorsVladimir Tolmachev, Fredrik Y Nilsson, Charles Widström, et al.
Cancer Biotherapy & Radiopharmaceuticals|September 25, 2003
[(111)In]Bz-DTPA-hEGF: Preparation and in vitro characterization of a potential anti-glioblastoma targeting agentAsa Liljegren Sundberg, Anna Orlova, Alexander Bruskin, et al.
Pageof 7

Showing results (41-50 of 63) with videos related to

Sort By:
Pageof 7
European Journal of Pharmaceutical Sciences : Official Journal of the European Federation for Pharmaceutical Sciences|December 27, 2024
Novel thermosensitive small multilamellar lipid nanoparticles with promising release characteristics made by dual centrifugationJonas K Koehler, Stefanie Schmager, Johannes Schnur, et al.
Journal of Materials Science. Materials in Medicine|January 31, 2014
Pre-incubation of chemically crosslinked hyaluronan-based hydrogels, loaded with BMP-2 and hydroxyapatite, and its effect on ectopic bone formationSonya Stenfelt, Gry Hulsart-Billström, Lars Gedda, et al.
Cancer Biotherapy & Radiopharmaceuticals|June 10, 2004
[177Lu]Bz-DTPA-EGF: Preclinical characterization of a potential radionuclide targeting agent against gliomaAsa Liljegren Sundberg, Lars Gedda, Anna Orlova, et al.
Cancer Biotherapy & Radiopharmaceuticals|October 25, 2002
Comparative biodistribution of the radiohalogenated (Br, I and At) antibody A33. Implications for in vivo dosimetryAnna Orlova, Johanna Höglund, Mark Lubberink, et al.
Tumour Biology : the Journal of the International Society for Oncodevelopmental Biology and Medicine|June 18, 2002
A new antibody recognizing the vIII mutation of human epidermal growth factor receptorLinda Ohman, Lars Gedda, Göran Hesselager, et al.
Physical Chemistry Chemical Physics : PCCP|January 6, 2023
Excited-state and charge-carrier dynamics in binary conjugated polymer dots towards efficient photocatalytic hydrogen evolutionAijie Liu, Sicong Wang, Hongwei Song, et al.
Plos One|July 7, 2012
Cellular effects of HER3-specific affibody moleculesLovisa Göstring, Magdalena Malm, Ingmarie Höidén-Guthenberg, et al.
International Journal of Pharmaceutics|April 26, 2021
Formulation development and upscaling of lipid nanocapsules as a drug delivery system for a novel cyclic GMP analogue intended for retinal drug deliveryDileep Urimi, Ronja Widenbring, Raúl Oswaldo Pérez García, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|April 29, 2006
111In-benzyl-DTPA-ZHER2:342, an affibody-based conjugate for in vivo imaging of HER2 expression in malignant tumorsVladimir Tolmachev, Fredrik Y Nilsson, Charles Widström, et al.
Cancer Biotherapy & Radiopharmaceuticals|September 25, 2003
[(111)In]Bz-DTPA-hEGF: Preparation and in vitro characterization of a potential anti-glioblastoma targeting agentAsa Liljegren Sundberg, Anna Orlova, Alexander Bruskin, et al.
Pageof 7